Clinical Trials Logo

Alzheimer's Disease clinical trials

View clinical trials related to Alzheimer's Disease.

Filter by:

NCT ID: NCT00090116 Completed - Alzheimer's Disease Clinical Trials

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Start date: March 2003
Phase: Phase 3
Study type: Interventional

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

NCT ID: NCT00087789 Completed - Alzheimer's Disease Clinical Trials

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Start date: June 2004
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total of four (Dose A and B) and six (Dose C) injections to target the basal forebrain region of the brain containing the nucleus basalis of Meynert (NBM). All study participants will be observed for a 24-month period and then followed annually.

NCT ID: NCT00086138 Completed - Depression Clinical Trials

Depression in Alzheimer's Disease-2

DIADS-2
Start date: July 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

NCT ID: NCT00083421 Completed - Alzheimer's Disease Clinical Trials

Effects of ONO-2506PO in Patients With Alzheimer's Disease

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

NCT ID: NCT00082602 Completed - Alzheimer's Disease Clinical Trials

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.

NCT ID: NCT00074529 Completed - Alzheimer's Disease Clinical Trials

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Start date: October 2003
Phase: Phase 2
Study type: Interventional

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

NCT ID: NCT00065689 Completed - Dementia Clinical Trials

High Intensity Light Therapy in Alzheimer's Disease

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bright light improves the sleep, mood, and behavior of persons with Alzheimer's disease and related dementias (AD) who live in long-term care settings and, if so, to determine the best timing for the light therapy. The light levels being used in the study have been shown to improve depression in persons with seasonal affective disorder (SAD) and to relieve sleep problems in persons with jet lag and other body rhythm disturbances. Because persons with AD often will not remain still in front of a fluorescent panel, this project has involved renovations in the study units that provide for even, regulated, high-intensity light in all public areas of the study settings.

NCT ID: NCT00056524 Completed - Stroke Clinical Trials

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).

NCT ID: NCT00056225 Completed - Alzheimer's Disease Clinical Trials

VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons with Alzheimer's disease.

NCT ID: NCT00051909 Completed - Alzheimer's Disease Clinical Trials

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.